Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure 2.

Figure 2

Follow-up studies and vaccine efficacy estimates for season 1, season 2, and across seasons on the prevention of acute respiratory infection (ARI) and lower respiratory tract disease (LRTD) with 3 or more signs/symptoms. All results are reported as point estimates in percent value and corresponding 95% confidence intervals. * = provisionary estimate for end of season 2 equals 77.8% (95.0% CI: 51.4, 91.1) [88].